Analysts have been eager to weigh in on the Financial sector with new ratings on S&P Global (SPGI – Research Report), Victory Capital ...

Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $433 and keeps a Sector Perform rating on the shares.

Davis Selected Advisers' 13F portfolio saw changes with stake increases in tech and travel, while reducing in financial and ...

Viatris Inc. (VTRS) is a global healthcare company formed through the merger of Mylan and Upjohn (a division of Pfizer) in ...

Healthcare’s resilience makes it a go-to sector during market volatility. With steady demand, innovation, and aging demographics driving growth, investors could consider investing in fundamentally ...

That’s because it’s gradually dawning on investors that they no longer can count on lower interest rates and inflation to support higher stock and bond prices. They are realizing that ...

A price to sales ("P/S") ratio of <1x is ... Analyst’s Disclosure: I/we have a beneficial long position in the shares of VTRS either through stock ownership, options, or other derivatives.

Viatris Inc. (VTRS), headquartered in Canonsburg, Pennsylvania, is a leading global healthcare company dedicated to empowering people worldwide to live healthier at every stage of life. With a market ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Elevate your confidence by analyzing investor sentiment and stock portfolio shifts, then make your own decisions.